Riboflavin (B2).

Methylenetetrahydrofolate reductase is an FAD-dependent flavoenzyme, and riboflavin supplies that FAD. In people carrying the MTHFR 677TT variant the enzyme binds FAD less tightly, which makes riboflavin status a bigger determinant of how much 5-methyltetrahydrofolate gets made. This is settled biochemistry rather than an inference.

Folate cannot cycle to its methyl form without a functioning FAD-dependent MTHFR step. Low riboflavin status therefore constrains folate metabolism regardless of folate intake. Folate status and riboflavin status are read together for that reason.

Pyridoxine 5-phosphate oxidase converts pyridoxine and pyridoxamine phosphates to the active pyridoxal 5-phosphate, and that enzyme requires FMN. Without riboflavin, dietary B6 cannot be fully activated. It is a direct upstream dependency, not a general B complex claim.

Pyridoxal 5-phosphate is already the active form, so it does not need the FMN-dependent oxidase that pyridoxine depends on. That makes the riboflavin dependency less relevant for this form specifically. The two B6 forms sit differently against riboflavin status for that reason.

Kynurenine 3-monooxygenase in the tryptophan to niacin route is FAD-dependent, so endogenous niacin synthesis stalls when riboflavin is short. Low riboflavin can therefore look like a niacin problem. Supplying preformed niacin bypasses the flavin-dependent step entirely.

Conversion of tryptophan along the kynurenine route toward NAD requires an FAD-dependent monooxygenase step. Riboflavin status shapes how much of a tryptophan load takes that path. This affects metabolite distribution rather than any single endpoint.

B12 supplies the methyl carrier for methionine synthase while riboflavin supplies the FAD that lets MTHFR generate the methyl donor. Both are needed for remethylation, at different points in the same cycle. Homocysteine is a marker of the pathway, not a disease endpoint.

Betaine remethylates homocysteine through betaine-homocysteine methyltransferase, a route that does not require folate or flavin cofactors. It therefore covers the pathway when the flavin-dependent branch is constrained. The two routes are parallel, not sequential.

Riboflavin deficiency impairs iron mobilisation and utilisation, and correcting it has been reported to improve the haematological response to iron in deficient populations. Flavin-dependent reductases participate in releasing iron from ferritin. The relationship is about how well iron is used, not about how much is swallowed.

Glutathione reductase is an FAD-dependent flavoenzyme that regenerates reduced glutathione from its oxidised disulfide form. Riboflavin status is measured in the laboratory using exactly this enzyme, through the erythrocyte glutathione reductase activation coefficient. Without flavin, recycled glutathione falls even when total glutathione intake is adequate.

Glutathione peroxidase is a selenoenzyme that consumes reduced glutathione, and glutathione reductase is the FAD-dependent enzyme that regenerates it. The two nutrients sit on opposite ends of the same recycling loop. Adequacy of one does not compensate for shortfall in the other.

NAC supplies cysteine for glutathione synthesis while riboflavin supports the flavin-dependent recycling of glutathione already made. Synthesis and regeneration are different constraints. Which one limits depends on the situation, so pairing them covers both.

Dihydrolipoamide dehydrogenase, the E3 component shared by the pyruvate and alpha-ketoglutarate dehydrogenase complexes, is an FAD-dependent flavoenzyme that regenerates oxidised lipoamide. Riboflavin is therefore embedded in lipoate-dependent chemistry. This is textbook enzymology, not a supplement claim.

Complex I and complex II both use flavin cofactors, FMN and FAD respectively, to pass electrons to the coenzyme Q pool. Riboflavin sits immediately upstream of ubiquinone in the transport chain. The pairing is common in mitochondrial support formulas for exactly this reason.

Carnitine carries fatty acids into the mitochondrion, and the first step of beta oxidation is run by FAD-dependent acyl-CoA dehydrogenases. Riboflavin supplies that FAD, together with the electron transfer flavoprotein that accepts the electrons. Both nutrients are needed for the same overall process at different points.

Pyruvate dehydrogenase needs thiamine pyrophosphate at the E1 step and FAD at the E3 step, so both vitamins serve the same complex. B complex products group them for that reason. Neither substitutes for the other.

Xanthine oxidoreductase and aldehyde oxidase carry both a molybdenum cofactor and FAD in the same enzyme. Either shortfall constrains the same reaction. This is enzymology rather than a clinical interaction.

Riboflavin is an efficient photosensitiser: under light it generates reactive oxygen species that degrade ascorbate and other light-sensitive nutrients in solution. This is a formulation and storage issue in clear liquids, not an issue in a capsule. Opaque packaging is the standard control.

Photoexcited riboflavin degrades folate in aqueous solution, which is why fortified liquid products carrying both are packed away from light. The interaction happens in the bottle, not in the body. It is a stability constraint on co-formulation.

Intestinal uptake runs through saturable riboflavin transporters RFVT1 and RFVT2, so absorbed fraction falls sharply as the single dose rises. Very large single doses mostly colour the urine. This limits the value of megadosing in one sitting.